%PDF-1.4
%
29 0 obj
<>
endobj
25 0 obj
<>
endobj
84 0 obj
<>stream
Acrobat Distiller 5.0 for Macintosh
2002-12-09T23:07:51Z
2024-03-28T18:35:39-07:00
2024-03-28T18:35:39-07:00
QuarkXPress. 4.11: AdobePS 8.7.2 (104)
application/pdf
Heather
2001-653.jan
uuid:2455300a-1dd2-11b2-0a00-900827bd3700
uuid:2455300d-1dd2-11b2-0a00-5b0000000000
endstream
endobj
14 0 obj
<>
endobj
15 0 obj
<>
endobj
30 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
102 0 obj
[106 0 R]
endobj
103 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
440 777 117 -27 re
f
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:1)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(40)Tj
ET
0 0 0 0 scn
/GS0 gs
109.25 59.1 396.47 -10.84 re
f
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 scn
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(harmful are corticosteroids? J Rheumatol 1997;24:415-6.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Landewe RBM, vandenBorne BEEM, Breedveld FC, Dijkmans)]TJ
2.175 -1.25 Td
[(BAC. Methotrexate ef)17.7 (fects in patients with rheumatoid arthritis)]TJ
0 -1.25 TD
[(with cardiovascular comorbidity)64.8 (. Lancet 2000;355:1616-7.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (L)55 (ynch JW)91.7 (, Kaplan GA, Cohen RD, )17.7 (T)35 (uomilehto J, Salonen JT)73.9 (. Do)]TJ
2.175 -1.25 Td
(cardiovascular risk factors explain the relation between)Tj
T*
[(socioeconomic status, risk of all-cause mortality)64.8 (, cardiovascular)]TJ
T*
[(mortality)64.9 (, and acute myocardial infarction? )54.8 (Am J Epidemiol)]TJ
0 Tc 0 Tw T*
(1996;144:934-42.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Reilly P)91.7 (A, Cosh JA, Maddison PJ, Rasker JJ, Silman )54.8 (AJ. Mortality)]TJ
2.175 -1.25 Td
(and survival in rheumatoid arthritis: a 25 year prospective study of)Tj
0 Tc T*
[(100 patients. )54.8 (Ann Rheum Dis 1990;49:363-9.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (W)79.9 (olfe F)79.7 (, Flowers N, )54.8 (Anderson J. )17.7 (The National Rheumatic Disease)]TJ
2.175 -1.25 Td
(Data Bank: case mix and severity characteristics of patients in)Tj
T*
[(rheumatological practice. )54.8 (Arthritis Rheum 1998;41 Suppl 9:S132.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (W)79.9 (olfe F)79.7 (.)-0.1 ( )17.7 (The ef)17.7 (fect of smoking on clinical, laboratory)64.8 (, and)]TJ
2.175 -1.25 Td
(radiographic status in rheumatoid arthritis [see comments]. )Tj
T*
(J Rheumatol 2000;27:630-7.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (W)79.9 (olfe F)79.7 (, Zwillich SH. )17.7 (The long-term outcomes of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis: )54.8 (A)-220.1 (23-year prospective, longitudinal study of total joint)]TJ
T*
(replacement and its predictors in 1,600 patients with rheumatoid)Tj
T*
[(arthritis. )54.8 (Arthritis Rheum 1998;41:1072-82.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Fries JF)79.7 (, Spitz PW)91.7 (, )36.8 (Y)99.8 (oung DY)128.8 (. )17.7 (The dimensions of health outcomes:)]TJ
2.175 -1.25 Td
(the health assessment questionnaire, disability and pain scales. )Tj
T*
(J Rheumatol 1982;9:789-93.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Fries JF)79.7 (, Spitz PW)91.7 (, Kraines RG, Holman HR. Measurement of)]TJ
2.175 -1.25 Td
[(patient outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (W)79.9 (are JE, Sherbourne CD. )17.7 (The MOS 36-item short-form health)]TJ
2.175 -1.25 Td
(survey \(SF-36\). 1. Conceptual framework and item selection. Med)Tj
T*
(Care 1992;30:473-83.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Hurst NP)110.7 (, Kind P)110.7 (, Ruta D, Hunter M, Stubbings )54.8 (A. Measuring)]TJ
2.175 -1.25 Td
[(health-related quality of life in rheumatoid arthritis: )17.7 (V)110.8 (alidity)64.8 (,)]TJ
33 38.75 Td
(responsiveness and reliability of EuroQol \(EQ-5D\). Brit J)Tj
T*
(Rheumatol 1997;36:551-9.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ. Measurement of the quality of life in)]TJ
2.175 -1.25 Td
(rheumatic disorders using the EuroQol. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;36:786-93.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ. Evidence of disordered symptom appraisal in)]TJ
2.175 -1.25 Td
(fibromyalgia: Increased rates of reported comorbidity and comor-)Tj
T*
[(bidity severity)64.8 (. Clin Exp Rheumatol 1999;17:297-303.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Little RJA, Rubin DB. Statistical analysis with missing data. New)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(Y)Tj
-0.00011 Tc 0.00729 Tw 0.6221 0 Td
[(ork: W)39.8 (iley; )-17.7 (1987;1-278.)]TJ
0.02499 Tw -2.7971 -1.25 Td
[(26.)-875.1 (Statistical Solutions. Solas 2.0. Cork:Statistical Solutions; 2000.)]TJ
T*
[(27.)-875.1 (Stata Corporation. Stata Statistical Software: Release 6.0. College)]TJ
2.175 -1.25 Td
(Station: Stata Corporation; 1999.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (McEntegart )54.8 (A, Capell HA, Creran D, Rumley )54.8 (A, )17.7 (W)79.9 (oodward M,)]TJ
2.175 -1.25 Td
(Lowe GD. Cardiovascular risk factors, including thrombotic)Tj
T*
(variables, in a population with rheumatoid arthritis. Rheumatology)Tj
T*
(Oxford 2001;40:640-4.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Liuzzo G, Biasucci LM, Gallimore JR, et al. )17.7 (The prognostic value)]TJ
2.175 -1.25 Td
(of C-reactive protein and serum amyloid a protein in severe)Tj
T*
(unstable angina. N Engl J Med 1994;331:417-24.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (van der )17.7 (W)79.9 (al )54.8 (AC, Becker )54.8 (AE. )54.8 (Atherosclerotic plaque rupture \321)]TJ
2.175 -1.25 Td
[(pathologic basis of plaque stability and instability)64.8 (. Cardiovasc Res)]TJ
0 Tc 0 Tw T*
(1999;41:334-44.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein)]TJ
2.175 -1.25 Td
(and other markers of inflammation in the prediction of)Tj
T*
(cardiovascular disease in women. N Engl J Med 2000;342:836-43.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ, )54.8 (Anderson JA. Inflammation as measured by)]TJ
2.175 -1.25 Td
(the ESR predicts cardiovascular mortality across all rheumatic)Tj
T*
[(disorders: a 25-year prospective study of 5,822 patients. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42 Suppl 9:S299.)Tj
ET
0 0 0 0 scn
438 770 120 -25 re
f
BT
0 0 0 1 scn
/T1_2 1 Tf
-0.00011 Tc 0 Tw 20.37 0 0 21 439 753.6089 Tm
(2001-653-5)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
32 0 obj
<>
endobj
43 0 obj
<>
endobj
34 0 obj
<>
endobj
73 0 obj
<>
endobj
89 0 obj
<>
endobj
37 0 obj
<>
endobj
39 0 obj
<>
endobj
35 0 obj
<>stream
HT;o0w>ō:G0XUЇcːo;܉pݏ355B©@PifAilě7{}~8])4
lQU
yqyxgkFlPiu%@k#.V>iJi6.һw_G7 Y3V\]p@Qςlncڲ@rA4͠`O&Px/i4谼0Odo_7:ɯ
endstream
endobj
38 0 obj
<>stream
H\{PSwo4!w[5MQ(L]AQy1"/!@ y!yQOy@ "QRܵ>ZՎQiٙ=g̙9s|g
B]P(U^<8u:*#!079*ʖEv%}eCܹe7v`
-KP0dRdARA\d/ K6!4Zsd7ŎҲum5[]dmײ_W,"+Wz7&2Dޕg1,5oK̢/s8*,zhV:RfK>6NoH2<2s-"L-.cgk_pph[=X 6bF6ߛۗٛٛ֕ܚzSp8\%>rw؎Ե(wVfBɈvF!Hyͧkb[vPv
D1ؐ}~Aw182k_^z z
K^@_ uk,)jBE<~tz
=
l4P%HyY,H^k@x[7AjeT6[[/kr0AP8,^eA' %L%rxP 9U):Es;fTRZ2gc=`߽1͡o9nmcq4%pxnTL<gtҦu.TU=e BpbBÂwGC̵?JC!rV2@Y'߾j~F>7=
:<473 ^bgdcd=c18V56=JgqnT37ŏ9 lZ4_OdD~ؾHNW!@^|ڨo(q44.aC`X%H
&t4-2D䇻x!pf 58ӾiKEti}LRU,l8py s?Po'LSa~hg;)ȍ"OrRCbU @HsT9y6)|OJh
ùEeHHu\&[C[h.)ӄ,BuDt^Qr)BϙD}_*jL.{f[oc mUx2:r |aX
yS7c)fZWF8t5ڭ*5hZ挿v8]ˇT^=w"I}JC_K>]9+^ sD\#yDP((H>9uV}\9dn2w:m{8<ec
v,-0um=-襱@KN6^^/MI1hzL(OH*9Bӫ33mVq[a;*\njۭ
Ε1%FަDJxd*(:X;@
gm4gX^ X#ϑ+